Esketamine Dosing Regimen for Lower Peak Exposure in MDD
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Chronic administration of esketamine is associated with an increased risk of mutagenicity, necessitating the need for a safer and more effective treatment regimen for major depressive disorder (MDD) that limits circulating blood levels of the drug.
Innovation Solution
A method involving an induction regimen of no more than 7 days with an effective amount of a rapid-acting antidepressant, followed by a treatment regimen of at least 28 days with oral administration of esketamine doses ranging from 5 mg to 40 mg, to manage MDD effectively while minimizing peak concentrations and overall risk.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If esketamine is administered chronically at higher doses to achieve sustained antidepressant effect, then the therapeutic efficacy is improved, but the risk of mutagenicity and genotoxic events increases
Solution Approach 1:
The patent implements a structured treatment protocol with an induction phase (days 1-7) using higher doses to achieve rapid antidepressant effect, followed by a maintenance phase (days 8-56) using lower doses to sustain therapeutic benefit while minimizing genotoxic exposure. This periodic dosing strategy allows the system to achieve therapeutic goals during the induction phase while reducing harmful effects during the maintenance phase.
Solution Approach 2:
The patent systematically changes the dosage parameter over time, transitioning from higher doses (e.g., 40-80 mg) during the induction phase to lower doses (e.g., 20-40 mg) during the maintenance phase. This dynamic parameter adjustment optimizes the balance between achieving sufficient plasma concentrations for therapeutic efficacy and maintaining exposure levels below those associated with increased mutagenicity risk.
2Reliability
If esketamine is administered at higher doses to ensure adequate plasma concentration, then the antidepressant effect is enhanced, but the peak concentrations increase leading to greater safety risks
Solution Approach 1:
The treatment protocol uses periodic dosing with an induction phase of higher frequency/dose followed by a maintenance phase of lower frequency/dose. This allows adequate plasma concentrations to be achieved during the induction phase for rapid antidepressant effect, while the maintenance phase sustains therapeutic levels with lower peak concentrations that reduce safety risks.
Solution Approach 2:
The dosing regimen is dynamic rather than static, with the protocol explicitly transitioning from higher doses during days 1-7 to lower doses during days 8-56. This dynamic adjustment of dosing parameters allows the system to optimize therapeutic effect during the critical induction period while minimizing peak concentration-related risks during the extended maintenance period.
Data Source
AI summary
The present invention provides a dosage regimen for safe and efficacious administration of esketamine and rapid-acting antidepressants in the treatment of major depressive disorder (MDD)